Form 8-K VERTEX PHARMACEUTICALS For: Feb 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Vertex (VRTX) PT Raised to $220 at Cowen
February 6, 2019 7:52 AM ESTCowen analyst Phil Nadeau raised the price target on Vertex (NASDAQ: VRTX) to $220.00 (from $210.00) while maintaining a Outperform rating.
The analyst commented, "VRTX reported Q4 CF franchise revenue of $868.2MM vs consensus of $818.8MM, non-GAAP EPS of $1.30 vs. consensus of $1.08. 2019 revenue guidance... More
Maxim Group Downgrades Vertex (VRTX) to Hold
February 6, 2019 7:45 AM ESTMaxim Group analyst Jason McCarthy downgraded Vertex (NASDAQ: VRTX) from Buy to Hold.
The analyst highlighted:
Vertex reported 4Q18 with cystic fibrosis (CF) revenue of $868M, representing sequential growth of 11% and beating consensus of $816M; the results include Kalydeco revenue of $259M vs. $250.5M... More